Source: ERJ Open Res, 4 (4) 00051-2018; 10.1183/23120541.00051-2018
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Rhys Jones, Amaran Krishnan, Gemma L. Zeybel, Emily Dookun, Jeffrey P. Pearson, A. John Simpson, S. Michael Griffin, Chris Ward, Ian A. Forrest. Reflux in idiopathic pulmonary fibrosis: treatment informed by an integrated approach. ERJ Open Res, 4 (4) 00051-2018; 10.1183/23120541.00051-2018

Member's Comments

No comment yet.

Related content which might interest you: Nutritional assessment in patients with idiopathic pulmonary fibrosis: the NUTRIPF study Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Diagnosis of idiopathic pulmonary fibrosis: from guidelines to clinical practice Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF Source: Eur Respir J 2015; 46: 883-886 Year: 2015 Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines Source: Eur Respir Rev 2014; 23:193-214 Year: 2014 The lived experience of idiopatic pulmonary fibrosis: A qualitative study Source: International Congress 2016 – Respiratory nursing research: opening new perspectives on patient experiences Year: 2016 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Follow-up and nonpharmacological management of the idiopathic pulmonary fibrosis patient Source: Eur Respir Rev 2011; 20: 114-117 Year: 2011 Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry Source: Eur Respir J 2015; 46: 186-196 Year: 2015 The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches Source: Eur Respir J 2006; 28: 463-465 Year: 2006 Idiopathic pulmonary fibrosis: securing a confident diagnosis for every patient Source: Eur Respir J 2016; 47: 1057-1059 Year: 2016 Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012 Idiopathic pulmonary fibrosis: present understanding and future options Source: Eur Respir Rev 2011; 20: 132-133 Year: 2011 A supportive care decision aid tool for idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013